James C Mullen insider trades
Open-market stock purchases and sales by James C Mullen, Director at Thermo Fisher Scientific Inc, from SEC Form 4 filings since Feb 13, 2010.
Track record: 33% of 3 scored buys are up 5% or more since purchase, averaging -25%.
Recent trades
No open-market trades in the last 12 months.
Companies traded
- TMO Thermo Fisher Scientific Inc: other filings, last May 21, 2025
- EDIT Editas Medicine, Inc: 2 buys, 2 sales, last Apr 14, 2022
- PODD Insulet Corp: 1 buy, last May 16, 2018
- PTHN Patheon NV: other filings, last Aug 29, 2017
- PKI Perkinelmer Inc: 5 sales, last Nov 14, 2014
- PTI Patheon Inc: 20 buys, last Mar 11, 2014
- BIIB Biogen Idec Inc: 2 sales, last Jun 8, 2010